What Happened?
Gaithersburg, MD-based Novavax Appointed Jim Kelly as Executive Vice President and Chief Financial Officer
About the Company
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
About the Person
Jim Kelly is Executive Vice President and Chief Financial Officer at Novavax. Previously, Jim held various senior HR leadership roles in the industry.
Info Source
News
Short Profile